Metamizole
As of the edition of 20 October 2026, Metamizole is a small molecule: marketed, first approved in 1949 (CH); acts on PTGS1 and PTGS2.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1956
- Kind
- Small molecule
- Brand name
- Minalgin
- First approved
- 10 May 1949 (CH)
- Approvals on record
- 3 in 2 regions
- Holder of the most recent approval
- Sanofi; 2 holders in all
- Withdrawn from market
- 1 January 1975 (in some regions)
- Registered trials
- 39, 2 stopped early
- Disease areas
- Nervous system; Mouth and teeth; Lungs and airways; Ear, nose and throat; Heart and blood vessels; Infections
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 15 | 9 | 1 | 0 |
| Phase 1 | 2 | 2 | 0 | 0 |
| Phase 2 | 2 | 2 | 0 | 0 |
| Phase 3 | 6 | 3 | 2 | 0 |
| Phase 4 | 14 | 9 | 2 | 2 |
| All trials | 39 |